Introduction
============

Gastric cancer is a worldwide health concern and is the second leading cause of cancer-related deaths in China.[@b1-cmar-10-705] Gastrectomy with proper perigastric lymph node dissection remains the cornerstone of radical resection of potentially curable gastric cancer. With the advantages of minimally invasive and better short-term outcomes, laparoscopic gastrectomy (LG) for gastric cancer has garnered tremendous popularity over open gastrectomy.[@b2-cmar-10-705],[@b3-cmar-10-705] Currently, extensive researches have reported that laparoscopy-assisted gastrectomy (LAG) is a safe and feasible procedure with better short-term outcomes and equivalent long-term survival outcomes compared with open gastrectomy (OG).[@b4-cmar-10-705]--[@b6-cmar-10-705] Robotic surgery has been introduced as a better operation method with several advantages, which could overcome the technical limitations of conventional laparoscopy. There is evidence that the robotic gastrectomy (RG) could help to overcome some technical difficulties encountered when performing laparoscopic surgery, such as lymph node dissection, handling deep-seated vessels, and intracorporeal anastomoses.[@b7-cmar-10-705]--[@b10-cmar-10-705] However, these studies mainly focused on early gastric cancer, and majority of them only evaluated short-term outcomes. There is still a lack of well-matched studies that report long-term outcomes of RG with D2 lymph node dissection for patients with advanced gastric cancer (AGC). We, therefore, designed this study to compare the short-and long-term outcomes of RG and LG for AGC using a propensity score-matching analysis.

Patients and methods
====================

Patients
--------

Patients with postoperative pathological diagnoses of AGC who underwent RG or LG were screened from the prospectively maintained gastric cancer database at the Department of Digestive Surgery, Xijing Hospital of Digestive Diseases, Fourth Military Medical University from August 2013 to March 2017. The inclusion criteria were as follows: 1) histologically confirmed adenocarcinoma by gastroscopy and pathological biopsy; 2) depth of invasion confined to pT2, pT3, or pT4a; 3) no distant metastasis or invasion to adjacent organs; 4) not combined with other malignancy; 5) no emergency operation; and 6) no preoperative chemotherapy or radiation therapy was performed. Ultimately, 454 patients were included in the analysis. The entire cohort included 125 and 329 patients who underwent RG and LG, respectively. To reduce the effect of potential confounding due to the limits of respective studies, we performed propensity score matching using a logistic regression model with the following variables: age, gender, comorbidities, tumor size, extent of resection, histologic type, pT stage, pN stage, and pTNM stage. We performed one-to-one matching using a 0.02 caliper width. Finally, the propensity score-matched cohort comprised 112 cases in each group. Pathologic staging was evaluated according to the 8th Union for International Cancer Control/American Joint Committee on Cancer staging system of gastric cancer.[@b11-cmar-10-705] Postoperative complications were recorded and classified according to the Clavien--Dindo classification system.[@b12-cmar-10-705],[@b13-cmar-10-705]

Surgical procedure
------------------

The patients chose the surgical procedure (RG vs LG) by their individual decision after they were informed of the advantages and risks of each procedure. Patients in the 2 groups underwent distal gastrectomy (DG) or total gastrectomy (TG) based on the location of tumor. D2 lymph node dissection was performed according to the Japanese Gastric Cancer Treatment Guidelines (version 3).[@b14-cmar-10-705] During TG, spleen-preserving No. 10 lymph node dissection and omentectomy were performed. The reconstruction type (gastroduodenostomy or gastrojejunostomy for DG and Roux-en-Y esophagojejunostomy for TG) was selected according to the surgeon's preference. The extracorporeal reconstructions were mostly conducted in our center. We routinely administered postoperative adjuvant chemotherapy with 5-fluorouracil and cisplatin. This study was approved by the ethics committee of Xijing Hospital, and written informed consent was granted by the patients.

Postoperative evaluation and follow-up
--------------------------------------

Postoperative complications were recorded as complications that occurred within 30 days after surgery. Patients were followed up every 3 months during the first 2 years and then every 6 months from 2 to 5 years. The length of follow-up was defined as the time from surgery to the final follow-up date of December 2017 or time of death. Cancer recurrence was diagnosed based on radiologic or histological signs of disease.

Statistical analysis
--------------------

The data were analyzed using SPSS, version 22.0 (SPSS Inc., Chicago, IL, USA). All continuous variables are presented as the mean ± SD. The chi-square test was used to compare categorical variables between the 2 groups, and the independent sample *t*-test or Mann--Whitney *U*-test was used to compare continuous variables. Overall survival (OS) curves were calculated using the Kaplan--Meier method and analyzed by the log-rank test. *P*-values \<0.05 were considered statistically significant.

Results
=======

Clinicopathologic characteristics
---------------------------------

The clinicopathological characteristics of the patients are summarized in [Table 1](#t1-cmar-10-705){ref-type="table"}. The background characteristics were well matched, with no significant differences in gender, age, body mass index (BMI), tumor size, extent of resection, histological type, pT stage, pN stage, pTNM stage, and comorbidities between the RG and LG groups.

Surgical outcomes and postoperative complications
-------------------------------------------------

The surgical outcomes and postoperative complications are summarized in [Table 2](#t2-cmar-10-705){ref-type="table"}. The intraoperative blood loss was significantly reduced in the RG group compared with the LG group (179.2 vs 234.9 mL, *P*=0.000). However, the operative time was significantly longer in the RG group than that in the LG group (261.7 vs 227.8 min, *P*=0.000). Additionally, the total cost of hospitalization was significantly higher in the RG group than that in the LG group (92365.0 vs 69476.5 RMB, *P*=0.000). No significant difference was found between the 2 groups in terms of number of harvested lymph nodes (29.5±9.6 vs 27.8±8.7, *P*=0.149), time to first flatus (2.6±0.6 vs 2.8±1.1, *P*=0.124), time to start liquid diet (1.6±0.7 vs 1.7±0.5, *P*=0.320), time to start soft diet (3.6±1.6 vs 3.9±2.0, *P*=0.179), and days of postoperative hospital stay (6.9±2.3 vs 7.0±3.8, *P*=0.718).

There was no intraoperative or 30-day postoperative mortality. The incidences of overall complications did not differ significantly between the RG and LG groups (13.4% vs 11.6%, *P*=0.686). Moreover, no significant differences were noted in the minor (Clavien--Dindo grade II) and major complication (Clavien--Dindo grade ≥ IIIa) rates between the 2 groups (6.3% vs 5.4%, *P*=0.775; 7.1% vs 6.3%, *P*=0.789; respectively). Regarding individual complications, the incidence of wound problem, anastomotic leakage, duodenal stump fistula, and abdominal infection were also similar between the 2 groups.

Surgical outcomes and postoperative complications in different phases
---------------------------------------------------------------------

To examine the learning curve effect, we performed subgroup analysis by dividing the patients into 2 phases. The initial and late phase both comprised 56 patients in each group. [Table 3](#t3-cmar-10-705){ref-type="table"} shows surgical outcomes and postoperative complications in different phase between the 2 groups. The operative time was significantly longer in the RG group than those in the LG group during the initial phase (286.0 vs 236.8 min, *P*=0.000). In the late phase, no significant differences were noted between the two groups (237.4 vs 218.8 min, *P*=0.060). The number of harvested lymph nodes, time to first flatus, time to start liquid diet, time to start soft diet, days of postoperative hospital stay, and incidence of overall postoperative complications were not significantly different between the RG and LG groups in the initial or late phase (*P*\>0.05).

Subgroup analysis of different related factors
----------------------------------------------

We evaluate the surgical outcomes of patients according to different related factors, including the extent of resection, age, BMI, depth of invasion, and tumor size. The surgical outcomes of subgroup analyses are summarized in [Tables 4](#t4-cmar-10-705){ref-type="table"}[](#t5-cmar-10-705){ref-type="table"}[](#t6-cmar-10-705){ref-type="table"}[](#t7-cmar-10-705){ref-type="table"}--[8](#t8-cmar-10-705){ref-type="table"}. The results indicated that the RG groups had less intraoperative blood loss in all subgroup analyses (*P*\<0.05). However, RG was associated with longer operation time and higher cost in all subgroup analysis. RG had more harvested lymph nodes in patients who underwent DG (28.77±11.00 vs 24.8±7.0, *P*=0.014) and patients with low BMI (29.0±8.6 vs 26.0±6.9, *P*=0.026). However, no statistical significant differences were observed in the comparison of other subgroups. No differences were found between the 2 groups regarding the time to first flatus, time to start liquid diet, postoperative hospital stay, and incidence of overall postoperative complications.

Follow-up result
----------------

Within a median follow-up period of 28 months (range 3--52 months), the recurrence rate was 18.8% (21/112) in the RG group and 21.4% (24/112) in the LG group, with no significant difference (*P*=0.617). The 3-year OS rates of the RG and LG groups were 78.6% and 74.1% (*P*=0.483, [Figure 1](#f1-cmar-10-705){ref-type="fig"}). Stratified analysis showed that the 3-year OS rates for the patients after RG and LG were as follows: a total of 90.0 % vs 94.4 % for the patients with stage IB (*P*=0.436, [Figure 2A](#f2-cmar-10-705){ref-type="fig"}), 81.8% vs 77.3 % for the patients with stage II (*P*=0.667, [Figure 2B](#f2-cmar-10-705){ref-type="fig"}), and 70.8 % vs 64.0 % for the patients with stage III (*P*=0.687, [Figure 2C](#f2-cmar-10-705){ref-type="fig"}). Comparisons of the OS rates did not show significant difference for any of the stages.

Discussion
==========

To date, a considerable number of studies have investigated the short-term outcomes of RG for gastric cancer.[@b15-cmar-10-705]--[@b18-cmar-10-705] However, the majority of these studies included patients at a relatively early stage, and few of them evaluated the outcomes of RG for AGC. Thus, we designed this study to compare the short- and long-term outcomes of RG and LG for AGC. Additionally, we used the propensity score-matching method to reduce bias.

In the present study, we observed that the RG group was associated with less blood loss compared with the LG group, which is consistent with the previous studies. Moreover, this advantage still exists when subgroup analysis was conducted. Junfeng et al[@b19-cmar-10-705] reported that the RG group had less intraoperative blood loss (101.4 vs 131.4 mL, *P*=0.017) and more harvested lymph nodes (34.6±10.9 vs 32.7±11.2, *P*=0.013) compared with the LG group. This could be attributed to the fact that RG has tremor filtration, the ability to scale motion, and is stereoscopic, which could improve a surgeon's dexterity, allow precise dissection, and avoid injury blood vessels. Our result showed a tendency favoring RG in terms of the number of harvested lymph nodes, although no significant difference was observed between the RG and LG groups.

Lymph node dissection is one of the key elements of radical gastrectomy. It has been reported that the number of lymph node dissection was related to patients' prognosis.[@b20-cmar-10-705]--[@b23-cmar-10-705] From the standpoint of AGC curability, gastrectomy with D2 lymph node dissection is required according to the Japanese Gastric Cancer Association guidelines.[@b24-cmar-10-705]--[@b26-cmar-10-705] However, the superiority of more harvested lymph nodes was not consistent among all studies. Pugliese et al[@b27-cmar-10-705] and Song et al[@b28-cmar-10-705] reported that the number of harvested lymph nodes in the RG group are less than those in the LG group, but these studies are in small sample size and the result was drawn from their initial experience. In addition, studies have demonstrated that surgeons become skilled in RG with the accumulation of experience of about 20--30 cases, which provides a short learning curve compared with LG.[@b29-cmar-10-705]--[@b33-cmar-10-705] Several meta-analyses revealed that harvested lymph nodes for RG and LG were similar, but they all showed a tendency favoring RG.[@b17-cmar-10-705],[@b34-cmar-10-705],[@b35-cmar-10-705] According to our experience, the advantage of RG is that it could enable the surgeons to perform more precise dissection and anastomoses. These superiorities are more obvious for difficult lymph node dissection (station 8a, 10, 11p, 12a), which remains the cornerstone of D2 lymphadenectomy. Moreover, the robotic system can provide a much more stable view and better exposure in narrow operating field. Regarding more complex surgery, such as the resection of gastric stump cancer, the robotic surgical system has the advantages of clear vision, flexible operation, and stable traction during the operation procedure, which is superior to the laparoscopic technique.

Postoperative complication is an important factor for evaluating the safety and feasibility of a surgical procedure. We evaluate the postoperative complications according the Clavien--Dindo classification system, which has proven to be a standardized classification for assessment for complications in many types of surgery. In the current study, we found that the incidences of overall complications were comparable between the RG and LG groups (13.4% vs 11.6%, *P*=0.686). Moreover, no significant differences were noted in the minor (Clavien--Dindo grade II) and major complication (Clavien--Dindo grade ≥ IIIa) rates between the 2 groups (6.8% vs 5.4%, *P*=0.775; 4.8% vs 6.8%, *P*=0.453; respectively). Furthermore, analyses of specified complications revealed that the rate of wound problem, anastomotic leakage, duodenal stump fistula, and abdominal infection were also similar between the 2 groups.

The extent of resection, age, BMI, depth of invasion, and tumor size could be factors associated with the short-term outcomes.[@b36-cmar-10-705]--[@b38-cmar-10-705] In this study, we performed analyses by grouping the patients according to different factors. We found that patients in the RG group were all associated with lower blood loss. Intraoperative blood loss has been shown to be associated with prognosis of patients in gastric cancer.[@b39-cmar-10-705],[@b40-cmar-10-705] Kamei et al reported that curative resection with lower blood loss can contribute to improved survival.[@b41-cmar-10-705] Moreover, the less intraoperative blood loss may promote postoperative recovery, especially for elderly patients. Our result revealed that RG patients had a tendency to recover fast after surgery, although no significant differences were found in respect of these indicators. Lee et al[@b7-cmar-10-705] reported that the superiority of RG was more obvious in high BMI patients when performing DG. In the present study, among patients in the high BMI group, RG was also associated with less intraoperative blood loss. Meanwhile, the RG group was comparable with the LG group in terms of other surgical outcomes. According to the present findings, it seems that optimal surgical outcomes may have already been achieved with LG, leaving little room for improvement via RG. Enhanced recovery after surgery protocols has been routinely applied to accelerate the postoperative recovery of patients with gastric cancer in our center since 2012, which could explain that the time to first flatus, time to start diet, and postoperative hospital stay were superior to those reported in previous studies.[@b17-cmar-10-705],[@b42-cmar-10-705]

Long-term survival outcomes are key indicator for assessing oncological safety. Therefore, the long-term outcomes are also important and necessary for the wide application of RG in AGC. Junfeng et al[@b19-cmar-10-705] reported that the 3-year OS rates of patients with gastric cancer in RG and LG groups were 68.1% and 63.7%, respectively, with a median follow-up of 17 months; the difference was not statistically significant. In a propensity-matched analysis of RG vs LG for gastric cancer from 2005 to 2009, no significant differences were found in 5-year OS rate (93.2% vs 94.2%, *P*=0.521) and disease-free survival rate (90.7% vs 92.6%, *P*=0.229) with a median follow-up of 85 months. However, patients in early stage account for 83.4% in the study reported by Obama et al.[@b43-cmar-10-705] In the present study, patients in stages II and III account for 83.0 % of all cases in propensity score-matched cohort, indicating a poor prognosis for these cases. The current study showed that the 3-year OS rate after RG was similar with those in LG with a median follow-up of 28 months (78.6% vs 74.1%, *P*=0.483). Regarding stratified stages, the 3-year OS was also comparable between the 2 groups. These results indicated that RG and LG had comparable long-term survival outcomes for AGC.

Financial cost may also be an important factor in driving the selection of surgery type.[@b44-cmar-10-705],[@b45-cmar-10-705] To examine cost-effectiveness of the RG and LG, we retrospectively reviewed the overall hospital expenditure and found that the cost of RG group was about 23,000 RMB more than that of the LG group. A recent meta-analysis reported that the RG groups cost about \$ 4000 more than the LG groups. In our clinical practice, the higher cost, longer operation time, and limited benefit to patients are the major stumbling block to the wide application of RG. Meanwhile, the long-term benefits of less intraoperative blood loss have not been proven yet. Additionally, there is also no published study about the quality of life after RG, which is often used to assess the surgical outcomes.[@b46-cmar-10-705],[@b47-cmar-10-705] We believe that these problems will be solved in the near future with the accumulation of surgeon's experience, reduced costs of surgery, and more high-quality research on this topic.

We admit that our study has several limitations. First, this is a retrospective study conducted at a single center with limited duration of follow-up. Additionally, the allocation of the operation method to either RG or LG may include a selection bias, which could not be offset by propensity score-matching method.

Conclusion
==========

RG with D2 lymph node dissection is safe and feasible for AGC in terms of both short- and long-term outcomes. The higher cost, longer operation time, and limited benefit are the major stumbling blocks to the wide application of RG. High-volume randomized controlled trials with sufficient follow-up are needed to confirm this rationale.
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###### 

Characteristics of patients

  Variables                        Entire cohort   *P*-value   Propensity score-matched cohort   *P*-value               
  -------------------------------- --------------- ----------- --------------------------------- ----------- ----------- -------
  Age (years)                      55.4±11.5       56.9±10.5   0.197                             55.6±11.3   56.1±11.1   0.725
  Gender (male/female)             84/41           229/100     0.621                             78/34       79/33       0.884
  Body mass index (kg/m^2^)        23.7±2.8        23.1±3.0    0.041                             23.6±2.9    23.6±3.0    0.856
  Tumor size (≤5.0/\>5.0 cm)       91/34           239/90      0.973                             83/29       84/28       0.878
  Comorbidities (present/absent)   25/100          85/244      0.195                             23/89       24/88       0.870
  Histological type                                            0.000                                                     0.494
   Well/moderately                 28              133                                           23          19          
   Poorly/undifferentiated         97              196                                           89          93          
  pT stage                                                     0.006                                                     0.960
   T2                              47              82                                            38          36          
   T3                              45              113                                           41          42          
   T4a                             33              134                                           33          34          
  pN stage                                                     0.048                                                     0.821
   N0                              41              97                                            36          35          
   N1                              42              86                                            36          35          
   N2                              25              66                                            25          27          
   N3a                             13              41                                            12          9           
   N3b                             4               39                                            3           6           
  pTNM stage                                                   0.031                                                     0.993
   IB                              24              37                                            20          18          
   IIA                             27              55                                            22          23          
   IIB                             24              72                                            22          21          
   IIIA                            26              64                                            25          25          
   IIIB                            17              53                                            16          19          
   IIIC                            7               48                                            7           6           

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** LG, laparoscopic gastrectomy; RG, robotic gastrectomy.

###### 

Surgical outcomes and postoperative complications

  Characteristics                   RG (n=112)        LG (n=112)        *P*-value
  --------------------------------- ----------------- ----------------- -----------
  Operation time (min)              261.7±63.9        227.8±45.8        0.000
  Estimated blood loss (mL)         179.2±66.8        234.8±139.5       0.000
  No. of retrieved lymph nodes      29.5±9.6          27.7±8.7          0.149
  Time to first flatus (d)          2.6±0.6           2.8±1.1           0.124
  Time to start liquid diet (d)     1.6±0.7           1.7±0.5           0.320
  Time to start soft diet (d)       3.6±1.6           3.9±2.0           0.179
  Postoperative hospital stay (d)   6.9±2.3           7.0±3.8           0.718
  Cost of hospitalization (RMB)     92,365.0±6015.0   69,476.5±5885.6   0.000
  Overall complications (%)         15 (13.4)         13 (11.6)         0.686
  Grade II (%)                      7 (6.3)           6 (5.4)           0.775
   Wound infection                  2                 1                 1.000
   Pneumonia                        2                 1                 1.000
   Pancreatitis                     1                 0                 1.000
   Severe anemia                    2                 4                 0.683
  Grade IIIa (%)                    4 (3.6)           5 (4.5)           1.000
   Wound problem                    0                 1                 1.000
   Abdominal infection              2                 0                 0.478
   Anastomosis leakage              1                 2                 1.000
   Duodenal stump fistula           1                 2                 1.000
  Grade IIIb (%)                    2 (1.8)           1 (0.9)           1.000
   Intra-abdominal bleeding         0                 1                 1.000
   Anastomosis bleeding             2                 0                 0.478
  Grade IV (%)                      2 (1.8)           1 (0.9)           1.000
   Heart failure                    1                 0                 1.000
   Respiratory failure              1                 1                 1.000
  Grade V (%)                       0 (0.0)           0 (0.0)           --
  Clavien-Dindo grade ≥ IIIa (%)    8 (7.1)           7 (6.3)           0.789

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** d, days; LG, laparoscopic gastrectomy; RG, robotic gastrectomy.

###### 

Comparison of the 2 surgery methods in different phases

  Variables                            Initial phase     Late phase                                                    
  ------------------------------------ ----------------- ----------------- ------- ----------------- ----------------- -------
  Age (years)                          54.4±11.1         56.4±11.7         0.351   56.8±11.4         55.9±10.6         0.643
  Gender (male/female)                 38/18             42/14             0.403   40/16             37/19             0.541
  Body mass index                      23.9±2.4          23.4±3.0          0.323   23.3±3.3          23.7±3.1          0.546
  Comorbidity (present/absent)         10/46             13/43             0.483   13/43             11/45             0.645
  Extent of resection (DG/TG)          31/25             33/23             0.703   35/21             33/23             0.699
  Operation time (min)                 286.0±57.7        236.9±48.7        0.000   237.4±60.9        218.8±41.0        0.060
  Estimated blood loss (mL)            183.9±75.6        243.8±141.0       0.006   174.5±56.9        225.9±138.7       0.012
  No. of retrieved lymph nodes         29.6±8.1          26.6±7.2          0.042   29.4±10.9         28.8±9.9          0.779
  Time to first flatus (days)          2.6±0.6           2.8±1.1           0.124   2.6±0.5           2.7±0.4           0.261
  Time to start liquid diet (days)     1.6±0.7           1.7±0.5           0.320   1.6±0.7           1.6±0.5           0.675
  Time to start soft diet (days)       3.6±2.0           3.9±2.0           0.179   3.4±1.2           3.6±0.9           0.470
  Postoperative hospital stay (days)   6.9±2.3           7.0±3.8           0.718   6.9±2.2           6.4±2.3           0.254
  Cost of hospitalization (RMB)        92,906.1±5288.7   69,924.2±5980.0   0.000   91,824.0±6667.3   69,028.8±5808.8   0.000

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** DG, distal gastrectomy; LG, laparoscopic gastrectomy; RG, robotic gastrectomy; TG, total gastrectomy.

###### 

Comparison of the 2 surgery methods in different resection extent

  Variables                            Distal gastrectomy   Total gastrectomy                                               
  ------------------------------------ -------------------- ------------------- ------- ----------------- ----------------- -------
  Age (years)                          55.2±11.6            54.1±54.1           0.593   56.2±10.8         59.0±10.5         0.360
  Gender (male/female)                 48/18                48/18               1.000   30/16             31/15             0.825
  Body mass index                      23.2±3.0             23.3±3.1            0.950   24.2±2.7          24.0±2.9          0.704
  Comorbidity (present/absent)         14/52                10/56               0.367   9/37              14/32             0.229
  Operation time (min)                 220.5±29.9           198.1±25.0          0.000   320.8±52.1        270.5±33.1        0.000
  Estimated blood loss (mL)            160.0±57.0           221.3±133.0         0.001   206.7±70.6        254.1±147.7       0.053
  No. of retrieved lymph nodes         28.8±11.0            24.8±7.0            0.014   30.6±7.0          32.0±9.1          0.406
  Time to first flatus (days)          2.5±0.7              2.6±1.1             0.489   2.8±0.5           3.1±1.1           0.086
  Time to start liquid diet (days)     1.5±0.5              1.6±0.4             0.372   1.8±0.8           1.9±0.6           0.533
  Time to start soft diet (days)       3.4±1.6              3.7±2.1             0.267   3.9±1.6           4.2±1.8           0.439
  Postoperative hospital stay (days)   6.6±2.3              6.7±2.3             0.820   7.3±2.3           7.6±5.2           0.777
  Overall complications (%)            7 (10.6)             7 (10.6)            1.000   8 (17.4)          6 (13.0)          0.562
  Cost of hospitalization (RMB)        89,274.7±4848.6      66,178.0±4072.8     0.000   96,769.0±4602.7   74,209.1±4758.6   0.000

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** LG, laparoscopic gastrectomy; RG, robotic gastrectomy.

###### 

Comparison of the 2 surgery methods in different age groups

  Variables                            Age ≤60           Age \>60                                                      
  ------------------------------------ ----------------- ----------------- ------- ----------------- ----------------- -------
  Gender (male/female)                 46/23             49/20             0.581   32/11             30/13             0.631
  Body mass index                      23.7±3.0          24.0±3.0          0.546   23.5±2.7          22.8±3.0          0.264
  Comorbidity (present/absent)         6/63              5/64              0.753   17/26             19/24             0.662
  Operation time (min)                 258.7±63.5        222.9±42.6        0.000   266.6±65.0        235.7±49.9        0.015
  Estimated blood loss (mL)            174.9±61.3        208.8±96.9        0.015   186.1±75.0        276.5±182.6       0.004
  No. of retrieved lymph nodes         27.9±10.2         26.4±7.7          0.334   32.1±7.9          29.8±9.8          0.252
  Time to first flatus (days)          2.4±0.6           2.5±0.4           0.527   3.0±0.5           3.4±1.6           0.122
  Time to start liquid diet (days)     1.5±0.7           1.5±0.4           0.908   1.8±0.5           2.0±0.6           0.112
  Time to start soft diet (days)       3.4±1.4           3.4±0.5           0.929   3.9±1.8           4.7±3.0           0.129
  Postoperative hospital stay (days)   6.7±2.1           6.4±2.1           0.437   7.1±2.7           8.0±5.4           0.367
  Overall complications (%)            5 (7.2)           4 (5.8)           0.730   10 (23.3)         9 (20.9)          0.795
  Cost of hospitalization (RMB)        91,567.8±5510.0   68,331.3±4918.3   0.000   93,644.2±6614.1   71,314.1±6839.0   0.000

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** LG, laparoscopic gastrectomy; RG, robotic gastrectomy.

###### 

Comparison of the 2 surgery methods in different body mass index

  Variables                            BMI \<25          BMI ≥25                                                       
  ------------------------------------ ----------------- ----------------- ------- ----------------- ----------------- -------
  Age (years)                          56.8±11.2         57.8±11.0         0.621   53.4±11.2         53.6±10.8         0.360
  Gender (male/female)                 50/22             49/19             0.734   28/12             30/14             0.857
  Comorbidity (present/absent)         19/53             14/54             0.419   4/36              10/34             0.118
  Operation time (min)                 261.9±68.6        224.5±46.5        0.000   261.3±55.3        233.0±44.7        0.011
  Estimated blood loss (mL)            181.0±70.2        232.7±133.1       0.004   176.0±60.8        238.2±150.3       0.017
  No. of retrieved lymph nodes         29.0±8.6          26.0±6.9          0.026   30.5±11.2         30.4±10.4         0.066
  Time to first flatus (days)          2.6±0.6           2.8±1.1           0.187   2.7±0.7           2.9±1.1           0.440
  Time to start liquid diet (days)     1.6±0.7           1.7±0.6           0.680   1.6±0.5           1.7±0.5           0.231
  Time to start soft diet (days)       3.6±1.6           4.0±2.3           0.260   3.5±1.5           3.8±1.4           0.442
  Postoperative hospital stay (days)   7.1±2.6           6.7±2.6           0.378   6.5±1.5           7.5±5.1           0.217
  Overall complications (%)            10 (13.9)         8 (11.8)          0.707   5 (12.5)          5 (11.4)          0.860
  Cost of hospitalization (RMB)        92,660.0±5997.1   69,447.0±6138.0   0.000   91,834.0±6086.9   69,522.1±5541.9   0.000

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** BMI, body mass index; LG, laparoscopic gastrectomy; RG, robotic gastrectomy.

###### 

Comparison of the 2 surgery methods in different depth of invasion

  Variables                            No serosa invasion   Serosa invasion                                               
  ------------------------------------ -------------------- ----------------- ------- ----------------- ----------------- -------
  Age (years)                          55.8±12.5            56.2±12.6         0.890   55.5±10.7         56.1±10.4         0.732
  Gender (male/female)                 26/12                24/12             0.872   52/22             55/21             0.776
  Body mass index                      24.1±2.8             24.0±2.7          0.989   23.4±2.9          23.3±3.2          0.866
  Comorbidity (present/absent)         7/31                 9/27              0.492   58/16             61/15             0.776
  Operation time (min)                 280.7±71.1           242.4±51.3        0.010   252.0±58.0        221.0±41.5        0.000
  Estimated blood loss (mL)            178.2±65.8           258.3±159.0       0.006   179.7±67.7        223.7±128.9       0.010
  No. of retrieved lymph nodes         30.5±10.7            30.8±9.0          0.896   29.0±9.0          26.3±8.3          0.055
  Time to first flatus (days)          2.7±0.8              2.8±0.7           0.465   2.6±0.6           2.8±1.3           0.176
  Time to start liquid diet (days)     1.8±1.0              1.7±0.5           0.881   1.6±0.4           1.7±0.6           0.096
  Time to start soft diet (days)       3.6±2.2              3.7±1.2           0.771   3.6±1.2           4.0±2.2           0.154
  Postoperative hospital stay (days)   7.2±3.2              7.0±4.0           0.777   6.7±1.7           7.1±3.7           0.462
  Overall complications (%)            7 (18.4)             4 (11.1)          0.376   8 (10.8)          9 (11.8)          0.842
  Cost of hospitalization (RMB)        92,932.9±6380.2      70,763.1±5555.6   0.000   92,073.4±5841.9   68,867.0±5974.4   0.000

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** LG, laparoscopic gastrectomy; RG, robotic gastrectomy.

###### 

Comparison of the 2 surgery methods in different tumor size

  Variables                            Tumor size ≤5 cm   Tumor size \>5 cm                                               
  ------------------------------------ ------------------ ------------------- ------- ----------------- ----------------- -------
  Age (years)                          54.7±11.6          54.9±11.0           0.917   58.1±10.1         59.8±10.8         0.545
  Gender (male/female)                 57/26              62/22               0.463   21/8              17/11             0.349
  Body mass index                      23.7±3.0           23.7±3.0            0.953   23.4±2.5          23.1±3.2          0.621
  Comorbidity (present/absent)         15/68              16/68               0.871   8/21              8/20              0.934
  Operation time (min)                 248.8±60.8         219.5±41.3          0.000   298.5±58.8        252.8±50.1        0.003
  Estimated blood loss (mL)            171.5±61.9         232.6±141.6         0.000   201.4±76.0        241.4±135.4       0.172
  No. of retrieved lymph nodes         28.2±9.9           27.0±8.5            0.399   33.2±7.4          30.0±9.1          0.140
  Time to first flatus (days)          2.6±0.7            2.7±1.1             0.347   2.8±0.5           3.1±1.2           0.144
  Time to start liquid diet (days)     1.6±0.7            1.7±0.5             0.953   1.6±0.4           1.9±0.7           0.052
  Time to start soft diet (days)       3.6±1.8            3.8±1.3             0.389   3.4±0.7           4.1±2.1           0.119
  Postoperative hospital stay (days)   6.9±2.6            6.8±3.1             0.810   6.8±1.5           7.7±5.4           0.378
  Overall complications (%)            11 (13.3)          8 (9.5)             0.448   4 (13.8)          5 (17.9)          0.954
  Cost of hospitalization (RMB)        91,300.9±6265.8    68,616.0±5675.8     0.000   95,410.6±3935.9   72,058.0±5845.2   0.000

**Note:** Data are presented as mean ± standard deviation.

**Abbreviations:** LG, laparoscopic gastrectomy; RG, robotic gastrectomy.
